CorreGene

About CorreGene

Beijing CorreGene Biotechnology Co., Ltd. is a clinical-stage biotechnology firm established in 2016 by a group of Peking University alumni, including its founder and CEO, Dr. Xingwang Xie. Dr. Xie brings nearly two decades of experience in oncology and tumor immunology research from his time at Peking University People's Hospital and Peking University Hepatology Institute. CorreGene is focused on developing therapeutics based on T-cell receptors (TCRs) for treating solid tumors, chronic infections, and autoimmune diseases.

The company's core technology is a proprietary platform named SMART-TCR, which is designed to significantly improve the efficiency and success rate of TCR discovery and affinity optimization. This technology underpins CorreGene's dual-platform approach, which encompasses both TCR-T cell therapies (a form of adoptive cell transfer) and soluble TCR-based protein therapeutics known as TCR bispecifics (TCR-TCEs). This dual capability allows the company to develop treatments with different mechanisms of action. TCR-T therapies involve engineering a patient's own T-cells to recognize and fight cancer, noted for their potential efficacy in solid tumors, while TCR bispecifics are off-the-shelf protein drugs designed to engage T-cells to attack target cells.

CorreGene's business model is centered on the research, development, and eventual commercialization of these novel therapies. The company operates in the biopharmaceutical market, specifically within the cell and gene therapy sector. Its revenue generation will likely depend on the successful progression of its products through clinical trials, regulatory approval, and subsequent sales or licensing agreements with larger pharmaceutical partners. The company is actively advancing its pipeline, with several first-in-class drug candidates in development. These include a TCR-T cell therapy targeting the KRAS-G12 mutation, a significant oncogene, and what is described as the world's first TCR bispecific therapeutic targeting HPV infectious diseases. The company has initiated Investigator-Initiated Trials (IIT) for two of its TCR-T products and has received regulatory approval for clinical trials.